Navigation Links
Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Date:10/7/2008

ater this year. In addition, RDEA119 is being evaluated in a Phase 1 trial in patients with advanced cancer, and will be also be evaluated in a Phase 1/2 clinical trial in the fourth quarter of 2008 in combination with Nexavar(R) (sorafenib) in advanced cancer patients. The Company also plans to initiate a Phase 1 trial of RDEA436, its second-generation MEK inhibitor, in healthy volunteers, in the fourth quarter of this year.

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data show that RDEA436 is a potent in-vitro and in-vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
2. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
3. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
(Date:7/6/2015)... 6, 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... today announced the appointment of Joann V. Lofgren ... of Market Development, effective July 6, 2015. In this ... and executing on the company,s market and product development ... excited to welcome Joann to the OncoSec team and ...
(Date:7/5/2015)... 2015 Nihon University is pleased to ... Medical-Engineering Collaboration "Medicine Definitely Jumps Up with 8K" ... Tokyo, Japan . Many experts ... will present their achievements and future prospects on ... produced with 8K technology. (Documentation: ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
(Date:7/6/2015)... ... 2015 , ... doTERRA, the leading global essential oils company, is pleased to ... held the position as Director of the Hinckley Institute at the University of Utah, ... institute, Jowers states that he was ready for a new challenge, and out of ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN patient ... cancer. , “Receiving a cancer diagnosis is often the most traumatic experience of ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects have ... field to access and use this “Big Data” to improve health and cut costs ... Officer of the Mount Sinai Health System in New York City. Physicians will have ...
(Date:7/6/2015)... , ... July 06, 2015 , ... MD Now, the ... July 6. The newly constructed urgent care center will serve residents and visitors in ... addition to being MD Now’s 22nd South Florida location, the new facility will be ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program in the Livonia, ... Youth and announced a new charity campaign to raise funds in support of the ... abuse. Livonia Save Our Youth is a coalition created especially to educate and empower ...
Breaking Medicine News(10 mins):Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3
... of Coalgate, 60km west of Christchurch, died of blood poisoning ... . , ,An independent report into his death ... conference attended by his family. ,The report cleared ... failed Carroll by not offering him the best care. ...
... enhancement to decrease volume loss around the eyes, leads ... reviewed four cases where patients were injected superficially; all ... not be injected superficially, especially around the eyes, says ... not act as a dermal filler, which would be ...
... mother of three from Brisbane, Queensland in Australia died on ... cruise liner. She was apparently felled by a toxic combination ... fantasy. ,She had gone on the cruise with ... was friends with. ,Toxicology reports later revealed ...
... state authorities in US have found that psychiatric patients receive ... They are punched and hit or held in restraints for ... a patient's arm was broken as a nurse forcibly removed ... the growing strain on the state's overcrowded emergency rooms, doctors, ...
... devices -- including one designed to look at an infants ... use a needle filled with anesthetic to numb individual nerves ... they can quickly block nerve function in selected areas of ... patients from use of general anesthesia and sends them home ...
... number of lymph nodes that contain evidence of cancer ... chemotherapy and radiation to a treatment plan prior ... , The authors say their finding is particularly important ... to neoadjuvant therapies has been on the primary tumour ...
Cached Medicine News:Health News:New Zealand Authorities Concerned With Overcrowding in Hospitals 2Health News:New Zealand Authorities Concerned With Overcrowding in Hospitals 3Health News:Inquest of Date-rape Drug Victim Attracts Wide Attention in Australia 2Health News:Inquest of Date-rape Drug Victim Attracts Wide Attention in Australia 3Health News:Psychiatric Patients Ill-treated in Emergency Rooms, US Officials Say 2Health News:Psychiatric Patients Ill-treated in Emergency Rooms, US Officials Say 3Health News:Psychiatric Patients Ill-treated in Emergency Rooms, US Officials Say 4Health News:Mayo Clinic Physicians Have Adapted Real-time 3-D Ultrasound Imaging Devices 2Health News:Nodal Status is the Best Predictor in Esophageal Cancer 2Health News:Nodal Status is the Best Predictor in Esophageal Cancer 3
An automatic system for determining erythrocyte sedimentation rate (ESR) in EDTA tube and using cell counter racks....
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
The MICROsed-System is the ideal system back up support to be used as front-line instrument with small workloads....
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: